| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
David N Gill is Director at EOLS and has filed Form 4s across 3 companies. David N Gill's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $652K at current prices.
The biggest single holding is EOLS (~$640K) as Director. The EOLS filings lean toward selling, a net 10,361 shares.
David N Gill has 15 Form 4 filings on record from February 2015 to February 2026, across 3 companies: Director at Evolus (EOLS), 2024–2026; Director at STRATA Skin Sciences (SSKN), 2018–2019; Director at Ocugen (OCGN), 2015–2018.
The 18 reported transactions were 8 option or other derivative awards, 4 stock awards, 4 open-market purchases and 2 open-market sales.
Counted by filing, the open-market trades come to 4 purchases worth about $25K and 1 sale worth about $131K.
The largest open-market purchase was 5,000 shares of OCGN at an average $1.92 on December 9, 2016, about $10K.
The only open-market sale was 10,361 shares of EOLS at an average $12.64 on May 14, 2024, about $131K. Twelve months later EOLS was down 22%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2024 | EOLS Evolus, Inc. | Director | Sell | 10,361 | $12.64 | $131,009.60 | -23.4% | +2.2% | -21.8% | |
| Aug 16, 2017 | OCGN Ocugen, Inc. | Director | Buy | 3,000 | $1.81 | $5,439.00 | +27.3% | - | - | |
| May 16, 2017 | OCGN Ocugen, Inc. | Director | Buy | 3,000 | $1.68 | $5,040.00 | +37.5% | - | - | |
| Dec 15, 2016 | OCGN Ocugen, Inc. | Director | Buy | 3,000 | $1.65 | $4,950.00 | +60.0% | - | - | |
| Dec 9, 2016 | OCGN Ocugen, Inc. | Director | Buy | 5,000 | $1.92 | $9,600.00 | New | - | - |